Research data published in JAMA Internal Medicine reveal no linked of the smoking cessation drugs Pfizer's Chantix, GlaxoSmithKline's Zyban with cardiovascular risk, as reported Centre Daily Times Monday.
The current findings extend the results of a prior study uncovering that the drugs did not elevate the risks of severe psychiatric problems including suicidal behaviour.
In the current study, the research team examined cardiovascular risks in adult smokers treated with Chantix, Zyban, nicotine or placebo.
The researchers observed that the risks of heart-related death and non-fatal heart attack were balanced across the four groups.
"The FDA is reviewing the findings of this study and substantial supporting documentation from the clinical trial, along with additional published medical literature, as we continue to evaluate this issue," noted agency spokesperson Michael Felberbaum.
To read more NewsPoints articles, click here.